CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if the combination is safe and helps the immune system fight cancer more effectively. Ab…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …

This early-phase study tests a new drug called IACS-6274, given alone or with other medicines, in people with advanced solid tumors (like melanoma, ovarian, or head and neck cancers) that haven't responded to standard treatments. The main goal is to find the safest dose and under…

This phase II trial is testing whether the combination of cabozantinib (a targeted drug) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head/neck cancers that have stopped responding to prior immunotherapy. Researchers will also see if two tumor bi…

This study looks at whether giving the cancer drug nivolumab as a shot at home is as good as getting it in a clinic. It aims to reduce the time, cost, and stress of traveling for treatment. About 50 adults with various advanced cancers will try both settings and report which they…

This study follows 250 young adult cancer survivors to see how their social relationships and physical activity change over time and how these factors affect their quality of life. Participants wear an activity tracker and complete surveys. The goal is to learn how to better supp…

This study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or g…

This study looks at how T cells change in people with advanced melanoma, lung, or other cancers during anti-PD-1 immunotherapy. Researchers will measure specific markers in blood samples to see if they can predict treatment response or resistance. The goal is to understand why so…